AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (20 mg or 25 mg IV weekly) + Bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 21
Study 30402678 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus + Bevacizumab
Number of subjects: 21
Study 30403300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir and intravenous immunoglobulin
Number of subjects: 5
Study 30404035 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic blacks
Number of subjects: 718
Study 30404035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 718
Study 30404035 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 718
Study 30404572 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30405397 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 0
Study 30405397 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study 30405414 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) over Dorsolateral Prefrontal Cortex
Number of subjects: 0
Study 30405414 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30405426 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 0
Study 30405526 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity Robot-assisted Hand Training
Number of subjects: 0
Study 30405526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills
Number of subjects: 12
Study 30405743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30406070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led diabetes self-management education
Number of subjects: 0
Study 30406070 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30406341 — intervention group
Group type: EXPERIMENTAL
Intervention: 401 ± 5 nm blue LED for 30 minutes
Number of subjects: 10
Study 30406948 — intervention group
Group type: EXPERIMENTAL
Intervention: New imputation method for recurrent event data
Number of subjects: 0
Study 30406948 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial model analysis
Number of subjects: 0
Study 30407304 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients with CHF
Number of subjects: 3506
Study 30407304 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation patients without CHF
Number of subjects: 3506
Study 30407512 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term pasteurization of breast milk (62°C for 5 seconds)
Number of subjects: 87
Study 30407512 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified intervention)
Number of subjects: 87
Study 30407512 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term pasteurization
Number of subjects: 87
Study 30407512 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 87
Study 30407514 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30407618 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-24.9)
Number of subjects: 185
Study 30407618 — intervention group
Group type: COMPARATOR
Intervention: Overweight BMI (25-29.9)
Number of subjects: 185
Study 30407618 — intervention group
Group type: COMPARATOR
Intervention: Obese BMI (30 or higher)
Number of subjects: 185
Study 30408135 — intervention group
Group type: EXPERIMENTAL
Intervention: wAIHA patients with venous thromboembolic events (VTE)
Number of subjects: 48
Study 30408135 — intervention group
Group type: COMPARATOR
Intervention: wAIHA patients without VTE
Number of subjects: 48
Study 30408135 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin ≥ 40 μmol/L
Number of subjects: 48
Study 30408135 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte count above 7x10(9)/L
Number of subjects: 48
Study 30408606 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based telephone intervention
Number of subjects: 528
Study 30408606 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual telephone counseling
Number of subjects: 528
Study 30408606 — intervention group
Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 528
Study 30408700 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 79
Study 30408788 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 92
Study 30408788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 30409150 — intervention group
Group type: EXPERIMENTAL
Intervention: Greyscale ultrasound (GS)
Number of subjects: 50
Study 30409150 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave elastography (SWE)
Number of subjects: 50
Study 30409150 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 50
Study 30409150 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric ultrasound (mpUS)
Number of subjects: 50
Study 30409537 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 459
Study 30409537 — intervention group
Group type: EXPERIMENTAL
Intervention: MD diagnosis
Number of subjects: 459
Study 30410313 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (Nivestim™) administered at home
Number of subjects: 171
Study 30410448 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg daily initially, up titrated to 0.4 mg daily in 2 weeks)
Number of subjects: 48
Study 30410448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (20 mg/m)
Number of subjects: 15
Study 30410772 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensor platform assessment at preoperative baseline, 3, 6, and 12 months postoperatively
Number of subjects: 100
Study 30410781 — intervention group
Group type: EXPERIMENTAL
Intervention: domperidone (14-day treatment)
Number of subjects: 90
Study 30410783 — intervention group
Group type: EXPERIMENTAL
Intervention: MT4C-In Care web-based intervention
Number of subjects: 37
Study 30411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 97
Study 30411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin (OPN)
Number of subjects: 97
Study 30411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte Chemoattractant Protein 1 (MCP1)
Number of subjects: 97
Study 30411151 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stents (DES)
Number of subjects: 905
Study 30411246 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of hydroxyethyl starch (HES) solutions
Number of subjects: 2170
Study 30411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided popliteal sciatic and saphenous ropivacaine block anaesthesia
Number of subjects: 21
Study 30411727 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects (Group A)
Number of subjects: 20
Study 30411727 — intervention group
Group type: COMPARATOR
Intervention: Old subjects (Group B)
Number of subjects: 20
Study 30411727 — intervention group
Group type: EXPERIMENTAL
Intervention: Female healthy volunteers in both groups
Number of subjects: 20
Study 30412238 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (subcutaneous); specific dosage and duration not mentioned.
Number of subjects: 0
Study 30412238 — intervention group
Group type: EXPERIMENTAL
Intervention: DT-EIA (drug-tolerant EIA); specific details not mentioned.
Number of subjects: 0
Study 30412238 — intervention group
Group type: COMPARATOR
Intervention: Original-EIA; specific details not mentioned.
Number of subjects: 0
Study 30412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 2452
Study 30412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (1.0 mg/kg)
Number of subjects: 2452
Study 30412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (2.0 mg/kg)
Number of subjects: 2452
Study 30412493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2452
Study 30412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (all doses)
Number of subjects: 2452
Study 30412681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable-isotope dilution ultraperformance chromatography multistage MS-based method for quantifying cortisol and 16 metabolites
Number of subjects: 0
Study 30412681 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable-isotope dilution ultraperformance chromatography multistage MS-based method
Number of subjects: 0
Study 30412926 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV services including rapid HIV testing and counselling, support for linkage to and retention in clinic-based HIV care.
Number of subjects: 146
Study 30412926 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV services
Number of subjects: 146
Study 30412926 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based services
Number of subjects: 146
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP1)
Number of subjects: 276
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-5)
Number of subjects: 276
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-3A)
Number of subjects: 276
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP3B)
Number of subjects: 276
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP4-5)
Number of subjects: 276
Study 30413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (all patients)
Number of subjects: 276
Study 30413396 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg orally once daily for 12 weeks
Number of subjects: 125
Study 30413396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30413396 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg
Number of subjects: 125
Study 30413399 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Nutrition Comics (INC) Web-based tool
Number of subjects: 89
Study 30413399 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 89
Study 30413504 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-test
Number of subjects: 104
Study 30413517 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of Acute Serious Illness in Children study (BASIC) intervention including genomic, transcriptomic, proteomic and metabolomic analyses of blood, urine, stool and throat swabs.
Number of subjects: 1017
Study 30413517 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires assessing quality of life and child behaviour.
Number of subjects: 1017
Study 30413543 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Mobile Doctor (iMD) intervention
Number of subjects: 47
Study 30413546 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid-insured visit rates in expansion states
Number of subjects: 872378
Study 30413546 — intervention group
Group type: COMPARATOR
Intervention: Privately insured visit rates in nonexpansion states
Number of subjects: 872378
Study 30413546 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin screenings in expansion states
Number of subjects: 872378
Study 30413559 — intervention group
Group type: EXPERIMENTAL
Intervention: Online family problem-solving treatment (OFPST)
Number of subjects: 359
Study 30413559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 359
Study 30413669 — intervention group
Group type: EXPERIMENTAL
Intervention: MBC-11 (0.5-10 mg/kg per day, administered daily for 5 days of every 4 weeks for up to four cycles)
Number of subjects: 15
Study 30413669 — intervention group
Group type: EXPERIMENTAL
Intervention: MBC-11
Number of subjects: 15
Study 30413829 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 508
Study 30413829 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological therapy
Number of subjects: 508
Study 30413837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg everolimus once daily + 50 mg CTX once daily
Number of subjects: 40
Study 30413960 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-FLAIR sequences
Number of subjects: 30
Study 30413960 — intervention group
Group type: EXPERIMENTAL
Intervention: SSFP sequences
Number of subjects: 30
Study 30413960 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30
Study 30414054 — intervention group
Group type: EXPERIMENTAL
Intervention: micro-fluid challenge (micro-FC; rapid central infusion of 50 ml)
Number of subjects: 61
Study 30414054 — intervention group
Group type: COMPARATOR
Intervention: traditional fluid challenge (FC; 5 ml/kg)
Number of subjects: 61
Study 30414054 — intervention group
Group type: EXPERIMENTAL
Intervention: extrasystolic method
Number of subjects: 61
Study 30414064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 710
Study 30414064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 710
Study 30414064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 30414064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID and 10 mg BID
Number of subjects: 710
Study 30414302 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Hemorrhagic Transformation (HT)
Number of subjects: 30
Study 30414302 — intervention group
Group type: EXPERIMENTAL
Intervention: ECASS classification of HT
Number of subjects: 30
Study 30414302 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision to reintroduce antiplatelet therapy
Number of subjects: 30
Study 30415208 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) serum levels
Number of subjects: 1754
Study 30415208 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitive troponin T (hs-TnT) serum levels
Number of subjects: 1754
Study 30415451 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg subcutaneously (SC) monthly
Number of subjects: 1458
Study 30415608 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized palliative home care
Number of subjects: 0
Study 30415608 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological treatment
Number of subjects: 0
Study 30416054 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP (Prolastin)
Number of subjects: 4
Study 30416770 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil/lymphocyte ratio (NLR) >11
Number of subjects: 269
Study 30416770 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte levels >10.5×10^9/L
Number of subjects: 269
Study 30416770 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) values
Number of subjects: 269
Study 30416787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective strategy with low tidal volume (Vt) (≤8 mL/kg) and limitation of the plateau pressure (Pplat) (≤30 cmH2O)
Number of subjects: 1814
Study 30416787 — intervention group
Group type: EXPERIMENTAL
Intervention: General acceptance of low Vt and limited Pplat
Number of subjects: 1814
Study 30416992 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention using Intervention Mapping
Number of subjects: 0
Study 30417511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node (SN) procedure
Number of subjects: 27
Study 30418117 — intervention group
Group type: EXPERIMENTAL
Intervention: mavrilimumab + methotrexate
Number of subjects: 0
Study 30418117 — intervention group
Group type: COMPARATOR
Intervention: methotrexate alone
Number of subjects: 0
Study 30418357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter for 10-35 days)
Number of subjects: 49
Study 30418357 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 49
Study 30418358 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 314
Study 30418358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccination
Number of subjects: 314
Study 30418358 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion confidence among HCPs regarding pertussis vaccination
Number of subjects: 314
Study 30418358 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred site for vaccine administration among HCPs
Number of subjects: 314
Study 30418539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral broad-spectrum antibiotics (ciprofloxacin, vancomycin, and metronidazole) for 7 days
Number of subjects: 13
Study 30418539 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 13
Study 30418574 — intervention group
Group type: COMPARATOR
Intervention: Children with healthy weight (HW)
Number of subjects: 76
Study 30418574 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with obesity (OB)
Number of subjects: 76
Study 30418599 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 1073
Study 30418599 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected participants
Number of subjects: 1073
Study 30418599 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants with limited smoking experience
Number of subjects: 1073
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of enteric pathogens in stool samples
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported diarrheal symptoms
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 1-11 months
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 24-48 months
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sanitary conditions (presence of feces or soiled diapers)
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine features (drop-hole covers, latrine walls) and presence of a water tap
Number of subjects: 759
Study 30419034 — intervention group
Group type: EXPERIMENTAL
Intervention: Any breastfeeding
Number of subjects: 759
Study 30419040 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1712
Study 30419040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1712
Study 30419227 — intervention group
Group type: EXPERIMENTAL
Intervention: TARRACO Score (based on clinical variables and cardiac troponin concentrations)
Number of subjects: 611
Study 30419227 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of TARRACO Score
Number of subjects: 611
Study 30419603 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody PB1016 TPVR
Number of subjects: 39
Study 30419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed electronic-learning (e-learning) using an animated video in phase-2
Number of subjects: 1694
Study 30419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning method (animated e-learning video + structured face-to-face training) in phase-3
Number of subjects: 1694
Study 30419884 — intervention group
Group type: COMPARATOR
Intervention: Comparison between phase-2 and phase-3
Number of subjects: 1694
Study 30419887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration therapy (drinking at least 2 L/day of hypotonic, oligomineral water low in sodium and minerals for at least 12 months)
Number of subjects: 25
Study 30419929 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT during radiation therapy
Number of subjects: 67
Study 30420252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness and cognitive assessments in patients
Number of subjects: 105
Study 30420252 — intervention group
Group type: COMPARATOR
Intervention: Cortical thickness and cognitive assessments in healthy control subjects
Number of subjects: 105
Study 30420252 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial least squares correlation analysis
Number of subjects: 105
Study 30420614 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib (ARQ 087)
Number of subjects: 29
Study 30420883 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g IVMP (1.0 g/day for 3 consecutive days) in DON (B1)
Number of subjects: 68
Study 30420883 — intervention group
Group type: COMPARATOR
Intervention: IVMP in every week schedule (cumulative dose 4.5 g) in GO (A3)
Number of subjects: 68
Study 30421265 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment for uncomplicated appendicitis
Number of subjects: 45
Study 30421633 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Lateral Approach (DLA)
Number of subjects: 60
Study 30421633 — intervention group
Group type: COMPARATOR
Intervention: Posterior Approach (PA)
Number of subjects: 60
Study 30421633 — intervention group
Group type: COMPARATOR
Intervention: Anterior Approach (AA)
Number of subjects: 60
Study 30421633 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 30421851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 4901
Study 30421851 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 4901
Study 30421858 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 39
Study 30421858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 39
Study 30421858 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in food preferences at 6 months
Number of subjects: 39